Article
Reproductive Biology
Wende Hao, Hongyu Zhao, Zhefeng Li, Jie Li, Jiahao Guo, Qi Chen, Yan Gao, Meng Ren, Xiaoting Zhao, Wentao Yue
Summary: By conducting an integrated bioinformatic analysis, potential biomarkers, risk factors, and drugs for EOC were identified, providing new insights for the diagnosis, condition appraisal, prevention, and treatment of EOC in the future.
JOURNAL OF OVARIAN RESEARCH
(2021)
Article
Multidisciplinary Sciences
Kira Philipsen Prahm, Claus Kim Hogdall, Mona Aarenstrup Karlsen, Ib Jarle Christensen, Guy Wayne Novotny, Estrid Hogdall
Summary: The study aimed to investigate differences in microRNA expression according to clinicopathological characteristics and predict cytoreductive outcome in ovarian cancer patients. One microRNA, miR-130a, was associated with serous histology and advanced FIGO stage, while seven other microRNAs were found to be significantly associated with clinicopathological characteristics but need further validation.
Article
Nutrition & Dietetics
Mariam M. AlHilli, Emily E. Rhoades, Danielle Chau, Surabhi Tewari, Adrian Reich, Alex Myers, Daniel J. Lindner, Justin D. Lathia, Renliang Zhang, Belinda Willard, Gail Cresci, Nathan A. Berger, Ofer Reizes
Summary: The impact of an unrestricted ketogenic diet (KD) on epithelial ovarian cancer (EOC) tumor growth, gene expression, and metabolite concentration was assessed in a mouse model. The KD-fed mice showed significantly increased tumor progression compared to the HF/LC and LF/HC-fed groups. The KD was associated with upregulation of fatty acid metabolism and regulation pathways, as well as enrichment of fatty acid and glutamine metabolites.
Article
Oncology
Lian Li, Jing Tian, Liwen Zhang, Luyang Liu, Chao Sheng, Yubei Huang, Hong Zheng, Fengju Song, Kexin Chen
Summary: In this study, NLR, PLR, and LMR were significantly associated with all stages and subtypes of EOC, with optimal cut-off points identified for predictive capability. High NLR and PLR levels increased the risk of endometrioid EOC in low CA125 patients, while low LMR levels were associated with increased risk of serous EOC. Preoperative inflammatory markers may serve as potential predictors for different histotypes of EOC alongside CA125.
Article
Oncology
Lucas Minig, Myriam Gracia Segovia, Octavio Arencibia, Cristina Zorrero, Lola Marti, Virginia Garcia Pineda, Juan Cespedes, Isabel Niguez, Blanca Gil-Ibanez, Berta Diaz-Feijoo, Soledad Fidalgo, Irene Valencia, Teodora Alonso-Gutierrez, Lorena Gonzalez, Amanda Veiga-Fernandez, Enrique Chacon, Isabel Negredo, Leticia Azcona Sutil, Mikel Gorostidi, Ignacio Zapardiel
Summary: This study aimed to determine the oncological outcomes and prognostic factors in women under 45 years old diagnosed with non-epithelial ovarian cancer. The study found that body mass index (BMI), residual disease, and sex-cord histology were important independent prognostic factors associated with worse outcomes in these women.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Caroline H. Hemmingsen, Susanne K. Kjaer, Ane Katrine Kaer Bennetsen, Christian Dehlendorff, Louise Baandrup
Summary: Reproductive factors have a significant impact on the risk of ovarian cancer, with parity, infertility, and oral contraceptive use showing different effects on the risk of different types of ovarian cancer.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Szymon Piatek, Iwona Szymusik, Piotr Sobiczewski, Wojciech Michalski, Magdalena Kowalska, Mariusz Oltarzewski, Mariusz Bidzinski
Summary: This study aimed to evaluate the recurrence and birth rates among patients with non-epithelial ovarian cancer. A total of 146 patients who underwent fertility-sparing surgery for germ cell (GCT) and sex cord-stromal tumors (SCST) were included. The 5- and 10-year disease-free survival rates were 91% and 83%, respectively. After a 24-month follow-up, the recurrence rate was higher than the rate of childbearing, but after 2 years, the childbearing rates exceeded the rate of recurrence.
Article
Biochemistry & Molecular Biology
Justin W. Gorski, Zhuwei Zhang, J. Robert McCorkle, Jodi M. DeJohn, Chi Wang, Rachel W. Miller, Holly H. Gallion, Charles S. Dietrich, Frederick R. Ueland, Jill M. Kolesar
Summary: The development of patient-derived tumor organoids from epithelial ovarian cancer has the potential to contribute significantly to precision medicine by testing chemotherapy sensitivity and investigating genetic drivers of drug resistance. This study identified one organoid line resistant to carboplatin, leading to a shorter progression-free survival and platinum-resistant recurrence. Gene expression analysis revealed interconnected pathways related to NF-kB, cellular differentiation, and B-cell receptor signaling in the context of carboplatin resistance.
Article
Biochemistry & Molecular Biology
Xinxin Huang, Juncheng Hao, Yan Qin Tan, Tao Zhu, Vijay Pandey, Peter E. Lobie
Summary: Patients with epithelial ovarian cancer are often diagnosed at an advanced stage, leading to poor overall prognosis. This review summarizes the functional significance of CXCL/CXCR chemokines in modulating EOC progression and discusses the current status and prospects of CXCR/CXCL-based theranostic strategies in EOC management.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Health Care Sciences & Services
Magdalena Bizon, Zofia Awizen-Panufnik, Wlodzimierz Sawicki
Summary: Ovarian cancer is difficult to diagnose early due to lack of symptoms, leading to poor prognosis. Inflammation is a key mechanism in this disease. Finding new markers for ovarian cancer is important for clinical use. CA125 and HE4 are commonly used markers, but new ones are still being sought. Inflammatory markers like C-reactive protein, procalcitonin, and interleukin-6 may have potential prognostic roles in diagnosing ovarian cancer.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Oncology
James Dilley, Aleksandra Gentry-Maharaj, Andy Ryan, Matthew Burnell, Ranjit Manchanda, Jatinderpal Kalsi, Naveena Singh, Robert Woolas, Aarti Sharma, Karin Williamson, Tim Mould, Lesley Fallowfield, Stuart Campbell, Steven J. Skates, Alistair McGuire, Mahesh Parmar, Ian Jacobs, Usha Menon
Summary: This study aims to compare symptoms in pre-clinical and clinically diagnosed early-stage cancers. The results suggest that early symptoms of early-stage cancer may be related to gastrointestinal issues and systemic fatigue, indicating the need to reconsider alert symptoms for early ovarian cancer.
GYNECOLOGIC ONCOLOGY
(2023)
Review
Endocrinology & Metabolism
Madison Pereira, Kathy Matuszewska, Colin Jamieson, Jim Petrik
Summary: Epithelial ovarian cancer is often diagnosed at advanced stages, presenting significant therapeutic challenges and low survival rates. Tumor heterogeneity and microenvironment diversity impact therapy response. Individual variations in endocrine milieu and immune profile affect treatment outcomes.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Kalika Kamat, Venkatesh Krishnan, Oliver Dorigo
Summary: Macrophage-secreted CCL23 contributes to the immune-suppressive TME in ovarian cancer by inducing exhausted phenotype of CD8+ T cells.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
June Y. Hou, Jocelyn S. Chapman, Ekaterina Kalashnikova, William Pierson, Karen Smith-McCune, Geovanni Pineda, Reena Marie Vattakalam, Alexandra Ross, Meredith Mills, Carlos J. Suarez, Tracy Davis, Robert Edwards, Michelle Boisen, Sarah Sawyer, Hsin-Ta Wu, Scott Dashner, Vasily N. Aushev, Giby George, Meenakshi Malhotra, Bernhard Zimmermann, Himanshu Sethi, Adam C. ElNaggar, Alexey Aleshin, James M. Ford
Summary: This study examined the utility of circulating tumor DNA (ctDNA) as a prognostic biomarker for epithelial ovarian cancer (EOC). The presence of ctDNA post-surgically was found to be highly predictive of reduced recurrence-free survival. CtDNA outperformed CA-125 in identifying patients at highest risk of recurrence.
GYNECOLOGIC ONCOLOGY
(2022)
Review
Oncology
Christine Fribert Thusgaard, Malene Korsholm, Kristina Magaard Koldby, Torben A. Kruse, Mads Thomassen, Kirsten Marie Jochumsen
Summary: The systematic review found that ctDNA is a potential biomarker for epithelial ovarian cancer, useful in diagnosis, treatment response monitoring, and prognostics. However, more studies are needed to determine the ideal methods and settings for the clinical use of ctDNA in EOC.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko
Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.
GYNECOLOGIC ONCOLOGY
(2024)